{
  "citations" : [],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166176623",
    "name" : "Annotation of CPIC Guideline for oxcarbazepine and HLA-B",
    "alternateDrugAvailable" : true,
    "cancerGenome" : false,
    "crossReferences" : [
      {
        "id" : 1447983473,
        "name" : "CPIC® Guideline for HLA genotype and Use of Carbamazepine and Oxcarbazepine – CPIC",
        "resource" : "URL",
        "resourceId" : "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/",
        "_url" : "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/",
        "version" : 1
      }
    ],
    "descriptiveVideoId" : "AFD2W7ugz2I",
    "dosingInformation" : false,
    "hasTestingInfo" : false,
    "history" : [
      {
        "id" : 1449167601,
        "date" : "2018-02-07T22:43:45.748-08:00",
        "description" : "guideline added",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450372858,
        "date" : "2019-03-20T14:12:21.385-07:00",
        "description" : "Added link to guideline video",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451890641,
        "date" : "2022-09-23T13:50:23.484-07:00",
        "description" : "fixed typo",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452137520,
        "date" : "2023-06-22T18:44:50.566-07:00",
        "description" : "Update supplemental table links",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":15100356,"title":"Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847474","crossReferences":[{"id":1449292006,"resource":"PubMed Central","resourceId":"PMC5847474","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847474"},{"id":1449292005,"resource":"PubMed","resourceId":"29392710","_url":"https://www.ncbi.nlm.nih.gov/pubmed/29392710"},{"id":1449292007,"resource":"DOI","resourceId":"10.1002/cpt.1004","_url":"http://dx.doi.org/10.1002%2Fcpt.1004"}],"objCls":"Literature","pubDate":"2018-04-01T00:00:00-07:00","terms":[{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : true,
    "pediatric" : false,
    "recommendation" : true,
    "relatedAlleles" : [
      {
        "objCls" : "Haplotype",
        "id" : "PA165954769",
        "symbol" : "HLA-B*15:02",
        "name" : "*15:02",
        "version" : 5
      }
    ],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA450732",
        "name" : "oxcarbazepine",
        "version" : 9
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA35056",
        "symbol" : "HLA-B",
        "name" : "major histocompatibility complex, class I, B",
        "version" : 40
      }
    ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1449163680,
      "html" : "<p>The CPIC Dosing Guideline for oxcarbazepine recommends an alternative drug for oxcarbazepine-naive patients carrying at least one copy of <em>HLA-B*15:02</em> due to the association of this allele with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).</p>\n",
      "version" : 0
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1451433632,
      "html" : "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/\" target=\"_blank\">CPIC&reg; guideline for oxcarbazepine and <em>HLA-B</em></a>.</p>\n<h3 id=\"december-2017\">December 2017</h3>\n<p><em>Accepted article preview online January 2018; Advance online publication February 2018.</em></p>\n<ul>\n<li>The 2017 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of carbamazepine expanded to include information on pharmacogenomic tests in dosing of oxcarbazepine. The updated guidelines were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC). Literature up to June 2016 was reviewed, recommendations and supplemental information were updated.</li>\n<li>Excerpts from the 2017 dosing guideline update:\n<ul>\n<li>&quot;There is evidence linking <em>HLA-B*15:02</em> genotype with the risk of carbamazepine- and oxcarbazepine-induced SJS/TEN.&quot;</li>\n<li>&quot;Data describing the relationship between <em>HLA-B*15:02</em> and <em>HLA-A*31:01</em> genotype and carbamazepine- or oxcarbazepine-induced cutaneous adverse reactions in pediatric patients are scarce. In the absence of data suggesting a different relationship between these <em>HLA</em> alleles and drug-induced hypersensitivity in pediatric patients, the recommendations may be used to guide use of carbamazepine and oxcarbazepine in both adult and pediatric patients.&quot;</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/carbamazepine/2017/CPIC_HLA_CBZ_OXC.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <em>HLA</em> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/carbamazepine/2017/CPIC_HLA_CBZ_OXC_Supplemental_Material.pdf\" target=\"_blank\">2017 supplement</a></li>\n<li><a href=\"https://www.pharmgkb.org/page/hlabRefMaterials\">HLA Gene-Specific Information Tables</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/report/current/drug_resource/oxcarbazepine-Drug_Resource_Mappings.xlsx\" target=\"_blank\">Oxcarbazepine Drug Resource Mappings</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/report/current/test_alert/oxcarbazepine_Pre_and_Post_Test_Alerts.xlsx\" target=\"_blank\">Oxcarbazepine Pre and Post Tests Alerts</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/images/flow_chart/Oxcarbazepine_CDS_Flow_Chart.jpg\" target=\"_blank\">Oxcarbazepine Clinical Decision Support Flow Chart</a></li>\n</ul>\n</li>\n</ul>\n<h3 id=\"table-1-oxcarbazepine-therapy-recommendations-based-on-hla-b-genotype\">Table 1: Oxcarbazepine therapy recommendations based on <em>HLA-B</em> genotype</h3>\n<p><em>Adapted from Tables 1 and 3 of the 2017 guideline update.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Likely phenotype</th>\n<th>Genotypes</th>\n<th>Examples of Diplotypes</th>\n<th>Phenotypic Implications</th>\n<th>Therapeutic Recommendations</th>\n<th>Classification of Recommendation <sup>a</sup></th>\n<th>Considerations for other aromatic anticonvulsants</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Homozygous for alleles other than <em>HLA-B*15:02</em></td>\n<td>Non-carrier of <em>HLA-B*15:02</em>.  No <em>HLA-B*15:02</em> alleles reported, often reported as &quot;negative&quot; on genotyping tests.</td>\n<td>*X/*X <sup>b</sup></td>\n<td>Normal or reduced risk of oxcarbazepine-induced SJS/TEN.</td>\n<td>Use oxcarbazepine per standard dosing guidelines.</td>\n<td>Strong</td>\n<td></td>\n</tr>\n<tr>\n<td>Heterozygote or homozygous for <em>HLA-B*15:02</em></td>\n<td>Carrier of <em>HLA-B*15:02</em>.  One or two <em>*15:02</em> alleles, often reported as &quot;positive&quot; on a genotyping test.</td>\n<td><em>*15:02</em>/*X <sup>b</sup><br/><em>*15:02</em>/<em>*15:02</em></td>\n<td>Increased risk of oxcarbazepine-induced SJS/TEN</td>\n<td>A. If patient is oxcarbazepine-naive, do not use oxcarbazepine.<br/>B. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within 3 months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.</td>\n<td>A. Strong<br/>B. Optional</td>\n<td>A. Other aromatic anticonvulsants (e.g. eslicarbazepine, lamotrigine, phenytoin, fosphenytoin and phenoarbital) have weaker evidence linking SJS/TEN with the <em>HLA-B*15:02</em> allele; however, caution should still be used in choosing an alternative agent.<br/>B. Previous tolerance of oxcarbazepine is not indicative of tolerance to other aromatic anticonvulsants.</td>\n</tr>\n</tbody>\n</table>\n<p><sup>a</sup> Rating scheme described in the 2017 update supplement (see above)</p>\n<p><sup>b</sup> *X = any <em>HLA-B</em> genotype other than <em>*15:02</em></p>\n<p><em>HLA-B</em> = human leukocyte antigen B</p>\n",
      "version" : 2
    },
    "version" : 19
  }
}